cbdMD (YCBD) Change in Accured Expenses (2016 - 2025)
cbdMD (YCBD) reported Change in Accured Expenses of -$276942.0 for Q4 2025, down 16.97% on a YoY basis from -$333531.2 in Q4 2024, and down 311.8% sequentially from -$67251.0 in Q3 2025.
cbdMD (YCBD) Change in Accured Expenses (2016 - 2025) Analysis & Trends
cbdMD (YCBD) has 10 years of Change in Accured Expenses data on file, last reported at -$276942.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses fell 16.97% year-over-year to -$276942.0; the trailing twelve-month figure through Dec 2025 stood at -$302055.0 (up 79.91% YoY), and the FY2025 full-year result was -$261883.0, up 76.7% from the prior year.
- Change in Accured Expenses fell to -$276942.0 in Q4 2025, from -$67251.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $763157.0 in Q2 2021 to a low of -$1.6 million in Q3 2024.
- A 5-year average of -$168466.0 and a median of -$53808.0 in 2025 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses slumped 1494.93% in 2023 and jumped 20577.44% in 2025, its largest moves.
- Tracing YCBD's Change in Accured Expenses over 5 years: stood at -$127254.0 in 2021, then jumped by 130.81% to $39204.0 in 2022, then surged by 262.95% to $142292.0 in 2023, then plunged by 266.4% to -$236770.0 in 2024, then declined by 16.97% to -$276942.0 in 2025.
- Business Quant data shows YCBD's Change in Accured Expenses at -$276942.0 in Q4 2025, -$67251.0 in Q3 2025, and $82503.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.15 Bn | 20.99 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | - |
| 10 | cbdMD | 4.66 Mn | 1.27 Mn | 3.00 Mn | -276,942.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -276,942.00 |
| Dec 31, 2025 | -276,942.00 |
| Sep 30, 2025 | -67,251.00 |
| Sep 30, 2025 | -67,251.00 |
| Jun 30, 2025 | 82,503.00 |
| Jun 30, 2025 | 82,503.00 |
| Mar 31, 2025 | -40,365.00 |
| Mar 31, 2025 | -40,365.00 |
| Dec 31, 2024 | -236,770.00 |
| Dec 31, 2024 | -236,770.00 |
| Sep 30, 2024 | -1.57 Mn |
| Sep 30, 2024 | -1.57 Mn |
| Jun 30, 2024 | 399.00 |
| Jun 30, 2024 | 399.00 |
| Mar 31, 2024 | 306,995.00 |
| Mar 31, 2024 | 306,995.00 |
| Dec 31, 2023 | 142,292.00 |
| Dec 31, 2023 | 142,292.00 |
| Sep 30, 2023 | -117,835.00 |
| Sep 30, 2023 | -117,835.00 |